Dataset: Transcription profiling by array of human cancer cells after treatment with buformin, metformin, phenformin, pyrvinium pamoate or versipelostatin
The unfolded protein response (UPR) is a cellular defense mechanism against glucose deprivation, a cell condition that occurs in solid...
The unfolded protein response (UPR) is a cellular defense mechanism against glucose deprivation, a cell condition that occurs in solid tumors. A key feature of the UPR is the activation of the transcription program that allows the cell to cope with endoplasmic reticulum (ER) stress. We used micoarrays to show that the UPR transcription program is disrupted by the antitumor macrocyclic compound versipelostatin (VST) and antidiabetic biguanides metformin, buformin and phenformin, depending on cellular glucose availability. Experiment Overall Design: Total 42 samples were prepared for RNA extraction and hybridization on Affymetrix microarrays. Experiment Overall Design: To induce the UPR, we treated cells (HeLa, HT-29, HT1080, MKN74) for 15 or 18 hours under ER stress conditions by replacing the medium with glucose-free medium or by adding either 2-Deoxy-D-glucose (2DG) or Tunicamycin (TM) to glucose-containing medium. UPR modulators (VST, biguanides or pyrvinium pamoate) were added at various final concentrations immediately after cells were placed in glucose-free medium or just before the chemical stressors were added to glucose-containing culture medium.
- Species:
- human
- Samples:
- 42
- Source:
- E-GEOD-13548
- PubMed:
- 19435925
- Updated:
- Dec.12, 2014
- Registered:
- Sep.11, 2014
Sample | cell line | organism part | time | dose | growth condition | compound | cell type |
---|---|---|---|---|---|---|---|
GSE13548GSM341386 | HeLa | cervix | 18 | normal | none | epithelial | |
GSE13548GSM341387 | HeLa | cervix | 15 | normal | none | epithelial | |
GSE13548GSM341388 | HeLa | cervix | 18 | 1 | normal | versipelostatin | epithelial |
GSE13548GSM341389 | HeLa | cervix | 18 | glucose free medium | none | epithelial | |
GSE13548GSM341390 | HeLa | cervix | 15 | glucose free medium | none | epithelial | |
GSE13548GSM341391 | HeLa | cervix | 18 | 1 | glucose free medium | versipelostatin | epithelial |
GSE13548GSM341392 | HeLa | cervix | 15 | 50 | glucose free medium | buformin | epithelial |
GSE13548GSM341393 | HeLa | cervix | 15 | 1500 | glucose free medium | metformin | epithelial |
GSE13548GSM341394 | HeLa | cervix | 15 | 15 | glucose free medium | phenformin | epithelial |
GSE13548GSM341395 | HeLa | cervix | 18 | 5 millimolar 2-deoxyglucose | none | epithelial | |
GSE13548GSM341396 | HeLa | cervix | 18 | 1 | 5 millimolar 2-deoxyglucose | versipelostatin | epithelial |
GSE13548GSM341397 | HeLa | cervix | 18 | 1 gram per milliliter tunicamycin | none | epithelial | |
GSE13548GSM341398 | HT-29 | colon | 18 | normal | none | epithelial | |
GSE13548GSM341398 | HT-29 | colon | 18 | normal | none | epithelial | |
GSE13548GSM341400 | HT-29 | colon | 18 | 10 | normal | versipelostatin | epithelial |
GSE13548GSM341401 | HT-29 | colon | 18 | glucose free medium | none | epithelial | |
GSE13548GSM341401 | HT-29 | colon | 18 | glucose free medium | none | epithelial | |
GSE13548GSM341403 | HT-29 | colon | 18 | 10 | glucose free medium | versipelostatin | epithelial |
GSE13548GSM341404 | HT1080 | bone | 18 | normal | none | fibroblast | |
GSE13548GSM341404 | HT1080 | bone | 18 | normal | none | fibroblast | |
GSE13548GSM341404 | HT1080 | bone | 18 | normal | none | fibroblast | |
GSE13548GSM341404 | HT1080 | bone | 18 | normal | none | fibroblast | |
GSE13548GSM341408 | HT1080 | bone | 18 | 3 | normal | versipelostatin | fibroblast |
GSE13548GSM341409 | HT1080 | bone | 18 | 300 | normal | buformin | fibroblast |
GSE13548GSM341410 | HT1080 | bone | 18 | 10000 | normal | metformin | fibroblast |
GSE13548GSM341411 | HT1080 | bone | 18 | 100 | normal | phenformin | fibroblast |
GSE13548GSM341412 | HT1080 | bone | 18 | 0.1 | normal | pyrvinium pamoate | fibroblast |
GSE13548GSM341413 | HT1080 | bone | 18 | glucose free medium | none | fibroblast | |
GSE13548GSM341414 | HT1080 | bone | 18 | 3 | glucose free medium | versipelostatin | fibroblast |
GSE13548GSM341415 | HT1080 | bone | 18 | 10 millimolar 2-deoxyglucose | none | fibroblast | |
GSE13548GSM341415 | HT1080 | bone | 18 | 10 millimolar 2-deoxyglucose | none | fibroblast | |
GSE13548GSM341417 | HT1080 | bone | 18 | 3 | 10 millimolar 2-deoxyglucose | versipelostatin | fibroblast |
GSE13548GSM341418 | HT1080 | bone | 18 | 300 | 10 millimolar 2-deoxyglucose | buformin | fibroblast |
GSE13548GSM341419 | HT1080 | bone | 18 | 10000 | 10 millimolar 2-deoxyglucose | metformin | fibroblast |
GSE13548GSM341420 | HT1080 | bone | 18 | 100 | 10 millimolar 2-deoxyglucose | phenformin | fibroblast |
GSE13548GSM341421 | HT1080 | bone | 18 | 0.1 | 10 millimolar 2-deoxyglucose | pyrvinium pamoate | fibroblast |
GSE13548GSM341422 | HT1080 | bone | 18 | 5 grams per milliliter tunicamycin | none | fibroblast | |
GSE13548GSM341423 | HT1080 | bone | 18 | 3 | 5 grams per milliliter tunicamycin | versipelostatin | fibroblast |
GSE13548GSM341424 | MKN74 | stomach | 18 | normal | none | epithelial | |
GSE13548GSM341425 | MKN74 | stomach | 18 | 1 | normal | versipelostatin | epithelial |
GSE13548GSM341426 | MKN74 | stomach | 18 | glucose free medium | none | epithelial | |
GSE13548GSM341427 | MKN74 | stomach | 18 | 1 | glucose free medium | versipelostatin | epithelial |